Galderma Group AG (PY3)
Market Closed
12 Jun, 06:06
€
185. 00
+5
+2.7778%
€
- Market Cap
- P/E Ratio
- Div Yield
10 Volume
- Eps
€ 180
Previous Close Want to track PY3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PY3 closed today higher at €185, an increase of 2.7778% from yesterday's close, completing a monthly increase of 2.2099% or €4. Over the past 12 months, PY3 stock gained 6.3218%.
PY3 pays dividends to its shareholders, with the most recent payment made on Apr 28, 2026. The next estimated payment will be in In 10 months on Apr 28, 2027 for a total of €0.35.
The last earnings report, released on Mar 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on SIX (CHF).
PY3 Chart
Galderma Group AG (PY3) FAQ
What is the stock price today?
The current price is €185.00.
On which exchange is it traded?
Galderma Group AG is listed on XMUN.
What is its stock symbol?
The ticker symbol is PY3.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Galderma Group AG ever had a stock split?
No, there has never been a stock split.
Galderma Group AG Profile
| Pharmaceuticals Industry | Healthcare Sector | Dr. Flemming Ornskov M.B.A., M.D., M.P.H. CEO | XMUN Exchange | CH1335392721 ISIN |
| CH Country | 7,676 Employees | 24 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Contact Information
Address: Zählerweg 10, Zug, Switzerland, 6300
Phone: 41 58 455 85 92
Website: https://www.galderma.com
